{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:44Z","timestamp":1788496304151,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>X-linked hypophosphatemia (XLH) is characterized by increased serum concentrations of fibroblast growth factor 23 (FGF23), hypophosphatemia and insufficient endogenous synthesis of calcitriol. Beside rickets, odonto- and osteomalacia, disproportionate short stature is seen in most affected individuals. Vitamin D analogs and phosphate supplements, i.e., conventional therapy, can improve growth especially when started early in life. Recombinant human growth hormone (rhGH) therapy in XLH children with short stature has positive effects, although few reports are available. Newly available treatment (burosumab) targeting increased FGF23 signaling leads to minimal improvement of growth in XLH children. So far, we lack data on the growth of XLH children treated with concomitant rhGH and burosumab therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-six patients received burosumab for at least 1\u00a0year after switching from conventional therapy. Of these, 23 received burosumab alone, while the others continued rhGH therapy after switching to burosumab. Children treated with burosumab alone showed a minimal change in height SDS after 1\u00a0year (mean\u2009\u00b1\u2009SD 0.0\u2009\u00b1\u20090.3 prepubertal vs. 0.1\u2009\u00b1\u20090.3 pubertal participants). In contrast, rhGH clearly improved height during the first year of treatment before initiating burosumab (mean\u2009\u00b1\u2009SD of height gain 1.0\u2009\u00b1\u20090.4); patients continued to gain height during the year of combined burosumab and rhGH therapies (mean\u2009\u00b1\u2009SD height gain 0.2\u2009\u00b1\u20090.1). As expected, phosphate serum levels normalized upon burosumab therapy. No change in serum calcium levels, urinary calcium excretion, or 25-OHD levels was seen, though 1,25-(OH)<jats:sub>2<\/jats:sub>D increased dramatically under burosumab therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To our knowledge, this is the first study on growth under concomitant rhGH and burosumab treatments. We did not observe any safety issue in this cohort of patients which is one of the largest in Europe. Our data suggest that continuing treatment with rhGH after switching from conventional therapy to burosumab, if the height prognosis is compromised, might be beneficial for the final height.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02562-9","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T08:02:34Z","timestamp":1668240154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-0975","authenticated-orcid":false,"given":"Diana-Alexandra","family":"Ertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Le Lorier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gleiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Trabado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Bensignor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Audrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volha","family":"Zhukouskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugurtha","family":"Berkenou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"2562_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, Lehrach H, Rowe PSN, Goulding JN, Summerfield T, Mountford R, Read AP, Popowska E, Pronicka E, Davies KE, O\u2019Riordan JLH, Econs MJ, Nesbitt T, Drezner MK, Oudet C, Pannetier S, Hanauer A, Strom TM, Meindl A, Lorenz B, Cagnoli B, Mohnike KL, Murken J, Meitinger T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11:130\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"2562_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1172\/JCI119276","volume":"99","author":"L Beck","year":"1997","unstructured":"Beck L, Soumounou Y, Martel J, et al. Pex\/PEX tissue distribution and evidence for a deletion in the 3\u2019 region of the Pex gene in X-linked hypophosphatemic mice. J Clin Investig. 1997;99(6):1200\u20139.","journal-title":"J Clin Investig"},{"issue":"7","key":"2562_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2562_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol. 2022;18(6):366\u201384.","journal-title":"Nat Rev Endocrinol"},{"key":"2562_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol JASN. 2006;17:1305\u201315.","journal-title":"J Am Soc Nephrol JASN"},{"key":"2562_CR6","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2562_CR7","doi-asserted-by":"publisher","first-page":"e72816","DOI":"10.1371\/journal.pone.0072816","volume":"8","author":"A Chanakul","year":"2013","unstructured":"Chanakul A, Zhang MY, Louw A, et al. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS ONE. 2013;8(9):e72816.","journal-title":"PLoS ONE"},{"key":"2562_CR8","doi-asserted-by":"publisher","first-page":"105501","DOI":"10.1016\/j.jsbmb.2019.105501","volume":"196","author":"S Christakos","year":"2020","unstructured":"Christakos S, Li S, De La Cruz J, et al. Vitamin D and the intestine: review and update. J Steroid Biochem Mol Biol. 2020;196:105501.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2562_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-021-00477-2","volume":"17","author":"A Arnold","year":"2021","unstructured":"Arnold A, Dennison E, Kovacs CS, et al. Hormonal regulation of biomineralization. Nat Rev Endocrinol. 2021;17(5):261\u201375.","journal-title":"Nat Rev Endocrinol"},{"key":"2562_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bone.2003.12.015","volume":"34","author":"D Miao","year":"2004","unstructured":"Miao D, Bai X, Panda DK, Karaplis AC, Goltzman D, McKee MD. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone. 2004;34:638\u201347.","journal-title":"Bone"},{"key":"2562_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bone.2018.08.004","volume":"116","author":"R Fuente","year":"2018","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez-Fr\u00edas O, Fern\u00e1ndez-Iglesias \u00c1, Hermida-Prado F, et al. Marked alterations in the structure, dynamics and maturation of growth plate likely explain growth retardation and bone deformities of young Hyp mice. Bone. 2018;116:187\u201395.","journal-title":"Bone"},{"key":"2562_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1172\/JCI106869","volume":"51","author":"S Balsan","year":"1972","unstructured":"Balsan S, Garabedian M. 25-Hydroxycholecalciferol. A comparative study in deficiency rickets and different types of resistant rickets. J Clin Investig. 1972;51:749\u201359.","journal-title":"J Clin Investig"},{"key":"2562_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0022-3476(05)82822-7","volume":"116","author":"S Balsan","year":"1990","unstructured":"Balsan S, Tieder M. Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height. J Pediatr. 1990;116:365\u201371.","journal-title":"J Pediatr"},{"key":"2562_CR14","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M \u017divi\u010dnjak","year":"2011","unstructured":"\u017divi\u010dnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R, et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab. 2011;96:E2097\u2013105.","journal-title":"J Clin Endocrinol Metab"},{"key":"2562_CR15","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13-30.","journal-title":"Endocr Connect"},{"key":"2562_CR16","first-page":"212","volume":"69","author":"O Makitie","year":"2008","unstructured":"Makitie O, Toiviainen-Salo S, Marttinen E, Kaitila I, Sochett E, Sipila I. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res. 2008;69:212\u201320.","journal-title":"Horm Res"},{"key":"2562_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s004670050340","volume":"11","author":"GS Reusz","year":"1997","unstructured":"Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, et al. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol. 1997;11:573\u20137.","journal-title":"Pediatr Nephrol"},{"key":"2562_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","volume":"127","author":"G Saggese","year":"1995","unstructured":"Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr. 1995;127:395\u2013402.","journal-title":"J Pediatr"},{"key":"2562_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","volume":"36","author":"A Rothenbuhler","year":"2017","unstructured":"Rothenbuhler A, Esterle L, Gueorguieva I, Salles J-P, Mignot B, Colle M, et al. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Horm IGF Res. 2017;36:11\u20135.","journal-title":"Growth Horm IGF Res"},{"key":"2562_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/BF02079060","volume":"154","author":"D Haffner","year":"1995","unstructured":"Haffner D, W\u00fchl E, Blum WF, Schaefer F, Mehls O. Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia. Eur J Pediatr. 1995;154:610\u20133.","journal-title":"Eur J Pediatr"},{"key":"2562_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1542\/peds.100.5.879","volume":"100","author":"MG Seikaly","year":"1997","unstructured":"Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics. 1997;100:879\u201384.","journal-title":"Pediatrics"},{"key":"2562_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, Beetz R, et al. Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol Berl Ger. 2018;33:447\u201356.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"2562_CR23","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics. 2004;113:e593\u20136.","journal-title":"Pediatrics"},{"key":"2562_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"2001","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138:236\u201343.","journal-title":"J Pediatr"},{"key":"2562_CR25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987\u201398.","journal-title":"N Engl J Med"},{"key":"2562_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:189\u201399.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2562_CR27","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet Lond Engl. 2019;393:2416\u201327.","journal-title":"Lancet Lond Engl"},{"key":"2562_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-21-0429","volume":"185","author":"VV Zhukouskaya","year":"2021","unstructured":"Zhukouskaya VV, Mannes I, Chaussain C, Kamenick\u00fd P, Audrain C, Lambert A-S, et al. Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. Eur J Endocrinol. 2021;185:475\u201384.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2562_CR29","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107(8):3241\u201353.","journal-title":"J Clin Endocrinol Metab"},{"key":"2562_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/BF01959355","volume":"151","author":"R Steendijk","year":"1992","unstructured":"Steendijk R, Hauspie RC. The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study. Eur J Pediatr. 1992;151:422\u20137.","journal-title":"Eur J Pediatr"},{"key":"2562_CR31","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med. 1991;325:1843\u20138.","journal-title":"N Engl J Med"},{"key":"2562_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1507\/endocrj.47.163","volume":"47","author":"J Miyamoto","year":"2000","unstructured":"Miyamoto J, Koto S, Hasegawa Y. Final height of Japanese patients with X-linked hypophosphatemic rickets: effect of vitamin D and phosphate therapy. Endocr J. 2000;47:163\u20137.","journal-title":"Endocr J"},{"key":"2562_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O Makitie","year":"2003","unstructured":"Makitie O, Kooh SW, Sochett E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol Oxf. 2003;58:163\u20138.","journal-title":"Clin Endocrinol Oxf"},{"key":"2562_CR34","first-page":"252","volume":"61","author":"E Sochett","year":"2004","unstructured":"Sochett E, Doria AS, Henriques F, Kooh SW, Daneman A, M\u00e4kitie O. Growth and metabolic control during puberty in girls with X-linked hypophosphataemic rickets. Horm Res. 2004;61:252\u20136.","journal-title":"Horm Res"},{"key":"2562_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fped.2020.00048","volume":"8","author":"S Mart\u00edn Ramos","year":"2020","unstructured":"Mart\u00edn Ramos S, Gil-Calvo M, Rold\u00e1n V, Castellano Mart\u00ednez A, Santos F. Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr. 2020;8:48.","journal-title":"Front Pediatr"},{"key":"2562_CR36","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ijms23020934","volume":"23","author":"R Fuente","year":"2022","unstructured":"Fuente R, Garc\u00eda-Bengoa M, Fern\u00e1ndez-Iglesias \u00c1, Gil-Pe\u00f1a H, Santos F, L\u00f3pez JM. Cellular and molecular alterations underlying abnormal bone growth in X-linked hypophosphatemia. Int J Mol Sci. 2022;23:934.","journal-title":"Int J Mol Sci"},{"key":"2562_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res. 2019;34:490\u20136.","journal-title":"J Bone Miner Res"},{"key":"2562_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2021.103187","author":"A Bonnet-Lebrun","year":"2021","unstructured":"Bonnet-Lebrun A, Linglart A, De Tienda M, Ouchrif Y, Berkenou J, Assi A, et al. Quantitative analysis of lower limb and pelvic deformities in children with X-linked hypophosphatemic rickets. Orthop Traumatol Surg Res OTSR. 2021. https:\/\/doi.org\/10.1016\/j.otsr.2021.103187.","journal-title":"Orthop Traumatol Surg Res OTSR"},{"key":"2562_CR39","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"M-L Piketty","year":"2020","unstructured":"Piketty M-L, Brabant S, Souberbielle J-C, Maruani G, Audrain C, Rothenbuhler A, et al. FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med. 2020;58:e267\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"2562_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","volume":"73","author":"RL Wasserstein","year":"2019","unstructured":"Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond \u201cp\u2009<\u20090.05.\u201d Am Stat. 2019;73:1\u201319.","journal-title":"Am Stat"},{"key":"2562_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1740-9713.2017.01021.x","volume":"14","author":"R Wasserstein","year":"2017","unstructured":"Wasserstein R, Spiegelhalter D. The ASA\u2019s p-value statement, one year on. Significance. 2017;14:38\u201341.","journal-title":"Significance"},{"key":"2562_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJMe1906559","volume":"381","author":"D Harrington","year":"2019","unstructured":"Harrington D, D\u2019Agostino RB, Gatsonis C, Hogan JW, Hunter DJ, Normand S-LT, et al. New guidelines for statistical reporting in the Journal. N Engl J Med. 2019;381:285\u20136.","journal-title":"N Engl J Med"},{"key":"2562_CR43","unstructured":"WHO Anthro Survey Analyser and other tools. https:\/\/www.who.int\/tools\/child-growth-standards\/software"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02562-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T14:09:25Z","timestamp":1668348565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02562-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2562"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02562-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Jard\u00e9 law in France, as the French Data Protection Authority (CNIL) approved the study, the need for written consent was waived. Patients and\/or their parents\/legal guardians were informed verbally of the objectives and procedures of the study and their verbal consent was obtained. They have the right to refuse to participate or to withdraw at any time by writing to .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VVZ reports speaker\u2019s fees and travel grants from Kyowa Kirin, not related to the manuscript submitted. AL reports receiving research grant support, honoraria from Kyowa Kirin, Novo Nordisk, Sandoz, Pfizer, and Merck Serono, also not related to the manuscript submitted. The other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}